PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25179419-7 2015 Plin5-deficient hepatocytes showed increased mitochondria proliferation, which could be explained by the increased expression and activity of PPARalpha stimulated by the increased NEFA levels. Fatty Acids, Nonesterified 180-184 peroxisome proliferator activated receptor alpha Mus musculus 142-151 25436917-7 2015 Moreover, the accumulation of ceramide was due to elevation of free fatty acids in ATGL-knockdown cardiomyocytes, which could be explained by the reduced activity of peroxisome proliferator-activated receptor (PPAR) alpha leading to imbalance of fatty acid uptake and oxidation. Fatty Acids, Nonesterified 63-79 peroxisome proliferator activated receptor alpha Mus musculus 166-221 24865983-10 2014 Finally, hepatic triglyceride and free fatty acid concentrations were increased 6.9- and 2.7-fold, respectively, in suckling PPARalpha-KO neonates. Fatty Acids, Nonesterified 34-49 peroxisome proliferator activated receptor alpha Mus musculus 125-134 24656387-4 2014 Reporter assays testing the transactivity of PPARalpha and AhR showed that free fatty acids from OFO, specifically the PO fraction, up-regulated PPARalpha transactivity and down-regulated AhR transactivity. Fatty Acids, Nonesterified 75-91 peroxisome proliferator activated receptor alpha Mus musculus 45-54 24656387-4 2014 Reporter assays testing the transactivity of PPARalpha and AhR showed that free fatty acids from OFO, specifically the PO fraction, up-regulated PPARalpha transactivity and down-regulated AhR transactivity. Fatty Acids, Nonesterified 75-91 peroxisome proliferator activated receptor alpha Mus musculus 145-154 21896918-9 2011 These results suggest that PPARalpha is activated by increased concentrations of free fatty acids that may arise from impaired fatty acid metabolism caused by altered levels of ATP, AMP, and ZMP after AICAR or adenosine treatment. Fatty Acids, Nonesterified 81-97 peroxisome proliferator activated receptor alpha Mus musculus 27-36 23769925-6 2013 Finally, the peroxisome-proliferator activated receptor alpha (PPARalpha) and sterol regulatory element-binding protein-1 (SREBP-1) pathways known to have a central role in regulating free fatty acid metabolism were downregulated in the livers, but not in the adipose or muscle, of C57BL/6J Npc1+/- mice compared to C57BL/6J Npc1+/+ mice. Fatty Acids, Nonesterified 184-199 peroxisome proliferator activated receptor alpha Mus musculus 13-61 23769925-6 2013 Finally, the peroxisome-proliferator activated receptor alpha (PPARalpha) and sterol regulatory element-binding protein-1 (SREBP-1) pathways known to have a central role in regulating free fatty acid metabolism were downregulated in the livers, but not in the adipose or muscle, of C57BL/6J Npc1+/- mice compared to C57BL/6J Npc1+/+ mice. Fatty Acids, Nonesterified 184-199 peroxisome proliferator activated receptor alpha Mus musculus 63-72 23766515-0 2013 Sphingosine kinase 1 is regulated by peroxisome proliferator-activated receptor alpha in response to free fatty acids and is essential for skeletal muscle interleukin-6 production and signaling in diet-induced obesity. Fatty Acids, Nonesterified 101-117 peroxisome proliferator activated receptor alpha Mus musculus 37-85 22345407-7 2012 A reciprocal 23% decrease in free fatty acid concentration was associated with reduced activation of peroxisome proliferator-activated receptor alpha. Fatty Acids, Nonesterified 29-44 peroxisome proliferator activated receptor alpha Mus musculus 101-149 21338618-0 2011 Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARalpha deterioration. Fatty Acids, Nonesterified 57-72 peroxisome proliferator activated receptor alpha Mus musculus 120-129 21338618-2 2011 Recently, free fatty acid (FFA) toxicities accompanying proteinuria were found to be a main cause of tubular damage, which was aggravated by insufficiency of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting the benefit of PPARalpha activation. Fatty Acids, Nonesterified 10-25 peroxisome proliferator activated receptor alpha Mus musculus 158-206 21338618-2 2011 Recently, free fatty acid (FFA) toxicities accompanying proteinuria were found to be a main cause of tubular damage, which was aggravated by insufficiency of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting the benefit of PPARalpha activation. Fatty Acids, Nonesterified 10-25 peroxisome proliferator activated receptor alpha Mus musculus 208-217 21338618-2 2011 Recently, free fatty acid (FFA) toxicities accompanying proteinuria were found to be a main cause of tubular damage, which was aggravated by insufficiency of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting the benefit of PPARalpha activation. Fatty Acids, Nonesterified 10-25 peroxisome proliferator activated receptor alpha Mus musculus 246-255 21338618-2 2011 Recently, free fatty acid (FFA) toxicities accompanying proteinuria were found to be a main cause of tubular damage, which was aggravated by insufficiency of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting the benefit of PPARalpha activation. Fatty Acids, Nonesterified 27-30 peroxisome proliferator activated receptor alpha Mus musculus 158-206 21338618-2 2011 Recently, free fatty acid (FFA) toxicities accompanying proteinuria were found to be a main cause of tubular damage, which was aggravated by insufficiency of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting the benefit of PPARalpha activation. Fatty Acids, Nonesterified 27-30 peroxisome proliferator activated receptor alpha Mus musculus 246-255 17764115-8 2008 We further demonstrated that stabilization of PPARalpha through a possible interaction with HCV core protein and an increase in nonesterified fatty acids, which may serve as endogenous PPARalpha ligands, in hepatocyte nuclei contributed to the core protein-specific PPARalpha activation. Fatty Acids, Nonesterified 128-153 peroxisome proliferator activated receptor alpha Mus musculus 46-55 20065157-1 2010 We recently found that endogenous (free fatty acids) and pharmacological (thiazolidinediones) agonists of nuclear receptor Peroxisome proliferator-activated receptor (PPAR)gamma stimulate renin transcription. Fatty Acids, Nonesterified 35-51 peroxisome proliferator activated receptor alpha Mus musculus 167-171 18445591-9 2008 With the dephosphorylation of PPARalpha, hepatic acetyl-CoA oxidase and apolipoprotein C-III mRNA expression was greatly affected and that was associated with substantial reductions in blood triglyceride and nonesterified fatty acid levels. Fatty Acids, Nonesterified 208-232 peroxisome proliferator activated receptor alpha Mus musculus 30-39 17764115-8 2008 We further demonstrated that stabilization of PPARalpha through a possible interaction with HCV core protein and an increase in nonesterified fatty acids, which may serve as endogenous PPARalpha ligands, in hepatocyte nuclei contributed to the core protein-specific PPARalpha activation. Fatty Acids, Nonesterified 128-153 peroxisome proliferator activated receptor alpha Mus musculus 185-194 17764115-8 2008 We further demonstrated that stabilization of PPARalpha through a possible interaction with HCV core protein and an increase in nonesterified fatty acids, which may serve as endogenous PPARalpha ligands, in hepatocyte nuclei contributed to the core protein-specific PPARalpha activation. Fatty Acids, Nonesterified 128-153 peroxisome proliferator activated receptor alpha Mus musculus 185-194 16857752-7 2006 This occurs despite the increased levels of free fatty acids caused by fasting in PPARalpha-null mice. Fatty Acids, Nonesterified 44-60 peroxisome proliferator activated receptor alpha Mus musculus 82-91 18669160-13 2008 In addition, we established a relation between increased PPAR-alpha expression in the adipose tissue and a change in the gene expression pattern, which explains the decrease of free fatty acids, triglycerides and the increase in insulin sensitivity. Fatty Acids, Nonesterified 177-193 peroxisome proliferator activated receptor alpha Mus musculus 57-67 16357043-6 2006 Furthermore, in wild-type mice HFD was associated with a significant increase in hepatic PPARalpha mRNA and plasma free fatty acids, leading to a PPARalpha-dependent increase in expression of PPARalpha marker genes CYP4A10 and CYP4A14. Fatty Acids, Nonesterified 115-131 peroxisome proliferator activated receptor alpha Mus musculus 146-155 16567507-7 2006 In diabetic PPARalpha-knockout mice, renal disease with accompanying albuminuria, glomerular sclerosis, and mesangial area expansion was more severe than in diabetic wild-type mice (P < 0.05) and was accompanied by increased levels of serum free fatty acids and triglycerides (P < 0.01). Fatty Acids, Nonesterified 244-260 peroxisome proliferator activated receptor alpha Mus musculus 12-21 16567507-12 2006 Taken together, PPARalpha deficiency appears to aggravate the severity of diabetic nephropathy through an increase in extracellular matrix formation, inflammation, and circulating free fatty acid and triglyceride concentrations. Fatty Acids, Nonesterified 180-195 peroxisome proliferator activated receptor alpha Mus musculus 16-25 16740970-3 2006 Treatment with PPAR-alpha agonist fenofibrate decreased body weight and fat pad weight and ameliorated liver steatosis in LD-fed mice with concomitant reduction in blood glucose, free fatty acid, triglyceride, serum insulin levels, and homeostasis model assessment index values. Fatty Acids, Nonesterified 179-194 peroxisome proliferator activated receptor alpha Mus musculus 15-25 16357043-6 2006 Furthermore, in wild-type mice HFD was associated with a significant increase in hepatic PPARalpha mRNA and plasma free fatty acids, leading to a PPARalpha-dependent increase in expression of PPARalpha marker genes CYP4A10 and CYP4A14. Fatty Acids, Nonesterified 115-131 peroxisome proliferator activated receptor alpha Mus musculus 146-155 15448592-5 2004 RESULTS: The PPARalpha agonist lowered plasma levels of glucose, insulin, triglycerides, and free fatty acids in ob/ob mice. Fatty Acids, Nonesterified 93-109 peroxisome proliferator activated receptor alpha Mus musculus 13-22 15665064-6 2005 Although PPAR-alpha-null mice also had elevated plasma free fatty acids, they had neither decreased cardiac GLUT-4 levels nor decreased glucose uptake during ischemia and, consequently, did not have poor recovery during reperfusion. Fatty Acids, Nonesterified 55-71 peroxisome proliferator activated receptor alpha Mus musculus 9-19 15665064-7 2005 We conclude that elevated plasma free fatty acids are associated with increased injury during ischemia due to decreased cardiac glucose uptake resulting from lower cardiac GLUT-4 protein levels, the levels of GLUT-4 being regulated, probably indirectly, through PPAR-alpha activation. Fatty Acids, Nonesterified 33-49 peroxisome proliferator activated receptor alpha Mus musculus 262-272 12594240-2 2003 The peroxisome proliferator-activated receptor alpha (PPARalpha) is a key regulator of FFA catabolism. Fatty Acids, Nonesterified 87-90 peroxisome proliferator activated receptor alpha Mus musculus 4-52 12594240-2 2003 The peroxisome proliferator-activated receptor alpha (PPARalpha) is a key regulator of FFA catabolism. Fatty Acids, Nonesterified 87-90 peroxisome proliferator activated receptor alpha Mus musculus 54-63 12485431-3 2002 Because a variety of endogenous free fatty acids are known activators, peroxisome proliferator-activated receptor alpha (PPAR-alpha) is a potential candidate for this key regulatory role. Fatty Acids, Nonesterified 32-48 peroxisome proliferator activated receptor alpha Mus musculus 71-119 12485431-3 2002 Because a variety of endogenous free fatty acids are known activators, peroxisome proliferator-activated receptor alpha (PPAR-alpha) is a potential candidate for this key regulatory role. Fatty Acids, Nonesterified 32-48 peroxisome proliferator activated receptor alpha Mus musculus 121-131 30429322-4 2018 Expression of the candidate target gene Ppara is decreased in white adipose tissue but not in the liver of mimic-treated (MIMIC) mice, and this is accompanied by increased circulating free fatty acids and hypertriglyceridemia. Fatty Acids, Nonesterified 184-200 peroxisome proliferator activated receptor alpha Mus musculus 40-45 12130701-5 2002 These alterations were correlated with changes in serum free fatty acid levels and, therefore, seem to be mediated by the peroxisome proliferator activated receptor-alpha. Fatty Acids, Nonesterified 56-71 peroxisome proliferator activated receptor alpha Mus musculus 122-170 11554740-4 2001 Free fatty acids can activate peroxisome proliferator-activated receptor alpha (PPARalpha), and activation of PPARalpha can promote PDK4 expression. Fatty Acids, Nonesterified 0-16 peroxisome proliferator activated receptor alpha Mus musculus 30-78 11554740-4 2001 Free fatty acids can activate peroxisome proliferator-activated receptor alpha (PPARalpha), and activation of PPARalpha can promote PDK4 expression. Fatty Acids, Nonesterified 0-16 peroxisome proliferator activated receptor alpha Mus musculus 80-89 11254743-5 2001 The diurnal variation in hepatic fatty acid and cholesterol synthesis was also abolished in the PPAR alpha-null animals and the variations in the concentration of plasma triacylglycerol, nonesterified fatty acids, and cholesterol were all attenuated. Fatty Acids, Nonesterified 187-212 peroxisome proliferator activated receptor alpha Mus musculus 96-106 30429322-6 2018 Importantly, simultaneously reducing free fatty acid plasma levels in MIMIC mice with either the lipolysis inhibitor acipimox or the PPARalpha agonist fenofibrate partially protects against these metabolic alterations. Fatty Acids, Nonesterified 37-52 peroxisome proliferator activated receptor alpha Mus musculus 133-142 26627259-3 2015 In turn, peroxisome proliferator-activated receptor alpha (PPARalpha) activation by free fatty acid (FFA), and cAMP response element-binding protein (CREB) activation by glucagon, lead to further metabolic alterations during the circadian active phase, as well as to aberrant activation of expression of the PCC components nuclear receptor subfamily 1, group D, member 1 (Nr1d1/RevErbalpha), Period (Per1 and Per2). Fatty Acids, Nonesterified 84-99 peroxisome proliferator activated receptor alpha Mus musculus 9-57 26627259-3 2015 In turn, peroxisome proliferator-activated receptor alpha (PPARalpha) activation by free fatty acid (FFA), and cAMP response element-binding protein (CREB) activation by glucagon, lead to further metabolic alterations during the circadian active phase, as well as to aberrant activation of expression of the PCC components nuclear receptor subfamily 1, group D, member 1 (Nr1d1/RevErbalpha), Period (Per1 and Per2). Fatty Acids, Nonesterified 84-99 peroxisome proliferator activated receptor alpha Mus musculus 59-68 26255030-2 2015 FFA act as endogenous ligands of peroxisome proliferator-activated receptors (PPAR), transcription factors regulating the expression of genes involved in lipid metabolism. Fatty Acids, Nonesterified 0-3 peroxisome proliferator activated receptor alpha Mus musculus 33-76 26255030-2 2015 FFA act as endogenous ligands of peroxisome proliferator-activated receptors (PPAR), transcription factors regulating the expression of genes involved in lipid metabolism. Fatty Acids, Nonesterified 0-3 peroxisome proliferator activated receptor alpha Mus musculus 78-82 26053032-8 2015 CYP2J2 ameliorates FFA-induced dyslipidemia via increased fatty acid oxidation mediated by the AMPK and PPARalpha pathways. Fatty Acids, Nonesterified 19-22 peroxisome proliferator activated receptor alpha Mus musculus 104-113